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Cardiovascular disease (CVD) represents the leading cause of death worldwide. A known environmental risk factor 
for the development of CVD is a diet rich in lipids and animal 
products1. In the past several years, a role for gut microbiota in 
the pathogenesis of CVD has been documented.2–5 The inter-
play between diet and cardiovascular health has been well 
studied, establishing that diets high in fat and lipids lead to 
poor cardiac outcomes.1 Although historically a causal role for 
the dietary nutrients cholesterol and fat has been the primary 
focus, more recent studies have highlighted additional contrib-
utory roles of alternative trimethylamine-containing dietary 
nutrients (eg, choline, phosphatidylcholine, and carnitine) and 
gut microbial metabolism.6 Recent studies have shown that 
there is a mechanistic link between gut microbe–dependent 
metabolism of dietary choline, phosphatidylcholine, carnitine, 
and CVD pathogenesis.2,4,5,7 Speciﬁcally, gut microbe metabo-
lism of these dietary nutrients results in production of trimeth-
ylamine, which is rapidly converted by host hepatic ﬂavin 
monooxygenase 3 into trimethylamine N-oxide (TMAO). 
Involvement of this metaorganismal (gut microbe and host) 
pathway in both TMAO formation and CVD pathogenesis 
includes studies that demonstrate the choline-, gut micro-
biota- and TMAO-dependent acceleration in atherosclerosis 
in animal models.2,4,7 Furthermore, reduction in TMAO levels 
through antisense oligonucleotide mediated inhibition in host 
hepatic ﬂavin monooxygenase 3 signiﬁcantly inhibited ath-
erosclerosis development in the low-density lipoprotein recep-
tor null mouse model, and the liver insulin receptor knockout 
trimethylamine-containing nutrients, is both elevated in the circulation of patients having heart failure and heralds 
worse overall prognosis. In animal studies, dietary choline or TMAO signiﬁcantly accelerates atherosclerotic lesion 
development in ApoE-deﬁcient mice, and reduction in TMAO levels inhibits atherosclerosis development in the low-
density lipoprotein receptor knockout mouse.
Methods and Results—C57BL6/J mice were fed either a control diet, a diet containing choline (1.2%) or a diet containing 
TMAO (0.12%) starting 3 weeks before surgical transverse aortic constriction. Mice were studied for 12 weeks after 
transverse aortic constriction. Cardiac function and left ventricular structure were monitored at 3-week intervals using 
echocardiography. Twelve weeks post transverse aortic constriction, myocardial tissues were collected to evaluate cardiac 
and vascular ﬁbrosis, and blood samples were evaluated for cardiac brain natriuretic peptide, choline, and TMAO levels. 
Pulmonary edema, cardiac enlargement, and left ventricular ejection fraction were signiﬁcantly (P<0.05, each) worse 
in mice fed either TMAO- or choline-supplemented diets when compared with the control diet. In addition, myocardial 
ﬁbrosis was also signiﬁcantly greater (P<0.01, each) in the TMAO and choline groups relative to controls.
Conclusions—Heart failure severity is signiﬁcantly enhanced in mice fed diets supplemented with either choline or the 
gut microbe–dependent metabolite TMAO. The present results suggest that additional studies are warranted examining 
whether gut microbiota and the dietary choline→TMAO pathway contribute to increased heart failure susceptibility. 
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Background—Trimethylamine N-oxide (TMAO), a gut microbe–dependent metabolite of dietary choline and other 
mouse model.8 Numerous mechanistic investigations demon-
strate a central role for the choline→TMAO metaorganismal 
pathway in cholesterol and sterol metabolism, macrophage 
phenotype, and reverse cholesterol transport.2,7,8,9 Importantly, 
recent microbial transplantation studies conﬁrmed that both 
TMAO production and atherosclerosis susceptibility are 
transmissible traits.5
Clinical studies have substantiated many of the above 
ﬁndings linking gut microbes and TMAO production to 
CVD. First, the original discovery of the pathway began with 
an unbiased metabolomics study of plasma from subjects 
undergoing elective cardiac evaluations, revealing a striking 
association between plasma levels of choline, TMAO, and 
betaine with cardiovascular risks among subjects (n=1876).2 
Examination of sequential subjects (n=1020) undergoing 
elective cardiac diagnostic catheterization shows signiﬁ-
cantly increased circulating levels of TMAO in patients with 
more extensive angiographic evidence of coronary artery 
disease.2 Furthermore, in a distinct cohort of subjects under-
going diagnostic cardiac catheterization (n=4007), elevated 
TMAO levels independently predicted increased risk of 
adverse cardiovascular outcomes, including heart attack, 
stroke, and death risk.3 Elevated TMAO levels have also been 
shown to herald worse overall prognosis among subjects 
with (and without) impaired kidney function, and to predict 
enhanced atherosclerotic burden.10,11 Recently, TMAO levels 
have been shown to be associated with a 3-fold enhanced 
risk for prevalent CVD among a community-based multieth-
nic population (hazard ratio, 3.17; 95% conﬁdence interval, 
1.05–9.51).12 Moreover, elevated TMAO plasma levels were 
reported in subjects (n=720) with stable heart failure (HF), 
with elevated levels predicting increased 5-year mortality 
risks (hazard ratio, 2.2; 95% conﬁdence interval, 1.4–3.4), 
an association that remained signiﬁcantly independent of 
traditional risk factors and cardiorenal indices.13 Elevated 
TMAO levels were also reported to predict increased risk 
of HF among both diabetic subjects (hazard ratio 4.6; 95% 
conﬁdence interval, 2.0–10.7) and nondiabetic (hazard ratio, 
1.9; 95% conﬁdence interval, 1.1–3.4) subjects alike.14 In 
further studies, elevated TMAO levels were observed among 
subjects (n=112) with extensive serial echocardiography, and 
similarly were associated with more advanced left ventricu-
lar (LV) diastolic dysfunction and predicted poorer long-term 
adverse clinical outcomes independent of cardiac and renal 
biomarkers.15 To date, no studies have tested whether dietary 
choline or TMAO directly promote the development and pro-
gression of cardiac dysfunction and HF. In the present study, 
we investigated the effects of dietary choline or TMAO in the 
setting of cardiac hypertrophy and HF after transverse aortic 
constriction (TAC).
Methods
Experimental Animals
C57BL6/J male mice aged 10 to 12 weeks (Jackson Laboratories, 
Bar Harbor, ME) were utilized for these studies. All animals were 
housed and maintained in an onsite temperature-controlled animal fa-
cility adhering to a 12-hour light/dark cycle and provided with water 
and rodent chow ad libitum. All animals were humanely cared for in 
accordance with the Principles of Laboratory Animal Care dictated 
by the National Society of Medical Research and the Guide for the 
Care and Use of Laboratory Animals by the National Institutes of 
Health (Publication No. 85-23, Revised 1996). All animal procedures 
were approved by Institutional Animal Care and Use Committee of 
both The Louisiana State University Health Sciences Center and the 
Cleveland Clinic.
Experimental Diets
Mice were maintained on either a chemically deﬁned control diet 
(TD.130104), a diet containing 0.12% TMAO added to the standard 
rodent chow (TD.07865), or a diet containing 1.2% choline added 
to the standard rodent chow (TD.09041) from Harlan Laboratories, 
Madison, WI as described previously. These diets were initiated at 
3 weeks prior to TAC surgery and maintained for an additional 12 
weeks.
TAC Protocol
Cardiac pressure overload and HF were induced using TAC surgery 
as described previously.16 The complete experimental protocol for 
these studies is depicted in Figure 1. Mice were anesthetized using 
xylazine (2 mg/kg) and ketamine (20 mg/kg) and maintained under 
anesthesia throughout the procedure by additional administration of 
xylazine (2 mg/kg) and ketamine (20 mg/kg) as needed. Mice were 
intubated and mechanically ventilated during the procedure using a 
Hugo Sachs type 845 minivent. Chest hair was removed from the 
mice by application of hair removal agent. The area was then cleaned 
using betadine and alcohol wipes alternating 3×. An incision was 
made proximally left of the midline of the chest, below the clavicle. 
The aorta was exposed using blunt dissection. A ligature was placed 
between the brachiocephalic artery and the left common carotid ar-
tery and secured to induce pressure overload. The chest was closed 
in layers, closing the muscle layer ﬁrst, then the skin. Mice were re-
moved from ventilation after pedal reﬂex returned, and it was deter-
mined that respiration could be maintained autonomously. Mice were 
placed in a recovery cage and supplied with 100% O2 until normal 
behavior returned.
Echocardiography Assessment
One week before TAC procedure, baseline transthoracic echo-
cardiogram was performed using 30-MHz probe on a Vevo 2100 
(Visualsonics) while under light anesthesia with isoﬂurane 
(0.25%–0.50%) supplemented with 100% O2, as described previ-
ously.16 After TAC procedure, echocardiography was performed for 
12 weeks at 3-week intervals.
Measurements of Serum Brain Natriuretic Peptide
Brain-type natriuretic peptide (BNP EIA kit; Phoenix Pharmaceuticals, 
Inc.) serum levels were determined by ELISA at 12 weeks after TAC 
as described previously.16
Histology and Immunochemistry
Hearts were collected at the speciﬁed time points and ﬁxed in 10% buff-
ered formalin, embedded in parafﬁn, and stained with either Masson tri-
chome or Picrosirius red to quantify ﬁbrosis as described previously.16
Quantiﬁcation of TMAO, Choline, Betaine, and 
Carnitine
Stable isotope dilution liquid chromatography-tandem mass spectrom-
etry (LC/MS/MS) was used for quantiﬁcation of the total choline, TMA, 
TMAO, carnitine, and betaine contents of diets, and the concentration of 
these analytes in plasma, as previously described.4,17 Brieﬂy, TMAO, cho-
line, betaine, and carnitine were monitored in positive MRM MS mode 
using characteristic precursor–product ion transitions: m/z 76→58, m/z 
104→60, m/z 118→59, and m/z 162→60, respectively. The internal stan-
dards d9(trimethyl)TMAO (d9-TMAO), d9(trimethyl)choline (d9-cho-
line), d9(trimethyl)betaine, and d3(methyl)carnitine (d3-carnitine) were 
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